feedback welcome

Nortriptyline-maprotiline

From Psychiatrynet

(Difference between revisions)
Jump to:navigation, search
[checked revision][draft revision]
 
(One intermediate revision not shown)
Line 3: Line 3:
| to = maprotiline
| to = maprotiline
| stop =  
| stop =  
-
* Gradually reduce dosage of nortriptylin to a maximum of 50 mg/day.
+
{{downNortriptyline}}
-
* When a dosage of 50 mg/day is reached, stop administration.
+
| start =  
| start =  
* No wash-out period is needed.  
* No wash-out period is needed.  
-
* Start administration of maprotiline the next day in a normal dosage of 25-75 mg/day.
+
* ''' Day 9: ''' start administration of maprotiline in a normal dosage of 25-75 mg/day.
| info =
| info =
-
* Both drugs are a TCA with anticholinergic properties, so a switch to a relatively high starting dose can be made.
+
* {{TCAantichol}}
* Actually maprotiline is a TCA with a carbon bridge, so it is also called TetraCyclicAntidepressant.
* Actually maprotiline is a TCA with a carbon bridge, so it is also called TetraCyclicAntidepressant.
-
{{review}}
 
}}
}}

Current revision as of 13:19, 2 November 2015

Nortriptyline
Type Antidepressant
Group TCA
links
Medscape Nortriptyline
PubChem 4543
PubMed Nortriptyline
Kompas (Dutch) Nortriptyline
Wikipedia Nortriptyline
Maprotiline
Type Antidepressant
Group NRI
links
Medscape Maprotiline
PubChem 4011
PubMed Maprotiline
Kompas (Dutch) Maprotiline
Wikipedia Maprotiline

Switch medication from nortriptyline to maprotiline.

Nietinrijdenbord.png Stop nortriptyline
Eenrichtingbord.png Start maprotiline
Infobord.png More information
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Navigation
About